[1]Büscher AK, Konrad M, Nagel M, et al. Mutations in podocyte genes are a rare cause of primary FSGS associated with ESRD in adult patients. Clin Nephrol. 2012;78(1):47-53. doi:10.5414/cn107320
[2]Isaranuwatchai S, Chanakul A, Ittiwut C, Ittiwut R, Srichomthong C, Shotelersuk V, Suphapeetiporn K, Praditpornsilpa K. Pathogenic variant detection rate by whole exome sequencing in Thai patients with biopsy-proven focal segmental glomerulosclerosis. Sci Rep. 2023 Jan 16;13(1):805. doi: 10.1038/s41598-022-26291-y. PMID: 36646731; PMCID: PMC9842604.
[3]Santín S, Bullich G, Tazón-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome.Clin J Am Soc Nephrol. 2011;6(5):1139-1148. doi:10.2215/CJN.05260610
[4]Gandzali Ngabe, P.E., Bonkano Baoua, D., Lengani, A.H.Y., Yattara, H., Kama Yatte, A., Loumingou, R., Tall, L., Ka, E.F., Niang, A. and Diouf, B. (2023) Focal Segmantal Glomerulosclerosis: Epidemiological, Clinico-Biological, Pathological, Etiological, Therapeutic and Evolutionary Profiles in Dakar. Open Journal of Nephrology, 13, 174-194. doi: 10.4236/ojneph.2023.132017.
[5]Rery TF Yuniarti, Ian Effendi, Zulkhair Ali, Novadian, Suprapti, Elfiani, Novandra AP, Dila Siti Hamidah, Fadil Pramudhya Husein, & Ika Kartika Edi P. (2024). Is It a Tumor or Not? A Case of Focal Segmental Glomerulosclerosis Secondary to Type 2 Diabetes with a Concomitant Renal Pseudotumor.Bioscientia Medicina : Journal of Biomedicine and Translational Research, 8(12), 5801-5813.
[6]Hoyer, J. R., Vernier, R. L., Najarian, J. S., Raij, L., Simmons, R. L., and Michael, A. F., Recurrence of idiopathic nephrotic syndrome after renal transplantation, Lancet, 1972, Vol 2(7773) p. 343-8.
[7]Dantal, J., Baatard, R., Hourmant, M., Cantarovich, D., Buzelin, F., and Soulillou, J. P., Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis: a one-center study of plasma exchange effects, Transplantation, 1991, Vol 52(5) p.
[8]Savin Virginia, J., Sharma, R., Sharma, M., McCarthy Ellen, T., Swan Suzanne, K., Ellis, E., Lovell, H., Warady, B., Gunwar, S., Chonko Arnold, M., Artero, M., and Vincenti, F., Circulating Factor Associated with Increased Glomerular Permeability to Albumin in Recurrent Focal Segmental Glomerulosclerosis, New England Journal of Medicine, 1991, Vol 334(14) p. 878-883.
[9] Gallon, L., Leventhal, J., Skaro, A., Kanwar, Y., and Alvarado, A., Resolution of recurrent focal segmental glomerulosclerosis after retransplantation, N Engl J Med, 2012, Vol 366(17) p. 1648-9.
[10] den Braanker, D. J. W., Maas, R. J., Deegens, J. K., Yanginlar, C., Wetzels, J. F. M., van der Vlag, J., and Nijenhuis, T., Novel in vitro assays to detect circulating permeability factor(s) in idiopathic focal segmental glomerulosclerosis, Nephrology Dialysis Transplantation, 2021, Vol 36(2) p. 247-256.
[11] Gauckler, P., Shin, J. I., Alberici, F., Audard, V., Bruchfeld, A., Busch, M., Cheung, C. K., Crnogorac, M., Delbarba, E., Eller, K., Faguer, S., Galesic, K., Griffin, S., Hrušková, Z., Jeyabalan, A., Karras, A., King, C., Kohli, H. S., Maas, R., Mayer, G., Moiseev, S., Muto, M., Odler, B., Pepper, R. J., Quintana, L. F., Radhakrishnan, J., Ramachandran, R., Salama, A. D., Segelmark, M., Tesař, V., Wetzels, J., Willcocks, L., Windpessl, M., Zand, L., Zonozi, R., and Kronbichler, A., Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?, Autoimmunity Reviews, 2020, Vol 19(11) p. 102671.
[12] Wei, C., Trachtman, H., Li, J., Dong, C., Friedman, A. L., Gassman, J. J., McMahan, J. L., Radeva, M., Heil, K. M., Trautmann, A., Anarat, A., Emre, S., Ghiggeri, G. M., Ozaltin, F., Haffner, D., Gipson, D. S., Kaskel, F., Fischer, D. C., Schaefer, F., and Reiser, J., Circulating suPAR in two cohorts of primary FSGS, J Am Soc Nephrol, 2012, Vol 23(12) p. 2051-9.
[13] Sharma, M., Zhou, J., Gauchat, J. F., Sharma, R., McCarthy, E. T., Srivastava, T., and Savin, V. J., Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier, Transl Res, 2015, Vol 166(4) p. 384-98.
[14] Doublier, S., Zennaro, C., Musante, L., Spatola, T., Candiano, G., Bruschi, M., Besso, L., Cedrino, M., Carraro, M., Ghiggeri, G. M., Camussi, G., and Lupia, E., Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS, PLOS ONE, 2017, Vol 12(11) p. e0188045.
[15] Meijers, B., Maas, R. J. H., Sprangers, B., Claes, K., Poesen, R., Bammens, B., Naesens, M., Deegens, J. K. J., Dietrich, R., Storr, M., Wetzels, J. F. M., Evenepoel, P., and Kuypers, D., The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis, Kidney International, 2014, Vol 85(3) p. 636-640.
[16] Müller-Deile, J., Sarau, G., Kotb, A. M., Jaremenko, C., Rolle-Kampczyk, U. E., Daniel, C., Kalkhof, S., Christiansen, S. H., and Schiffer, M., Novel diagnostic and therapeutic techniques reveal changed metabolic profiles in recurrent focal segmental glomerulosclerosis, Scientific Reports, 2021, Vol 11(1) p. 4577.
[17] Hou, S., Yang, B., Chen, Q., Xu, Y., and Li, H., Potential biomarkers of recurrent FSGS: a review, BMC Nephrology, 2024, Vol 25(1) p. 258.
[18]Wei, C., El Hindi, S., Li, J., Fornoni, A., Goes, N., Sageshima, J., Maiguel, D., Karumanchi, S. A., Yap, H. K., Saleem, M., Zhang, Q., Nikolic, B., Chaudhuri, A., Daftarian, P., Salido, E., Torres, A., Salifu, M., Sarwal, M. M., Schaefer, F., Morath, C., Schwenger, V., Zeier, M., Gupta, V., Roth, D., Rastaldi, M. P., Burke, G., Ruiz, P., and Reiser, J., Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis, Nat Med, 2011, Vol 17(8) p. 952-60.
[19] Chebotareva, N., Vinogradov, A., Cao, V., Gindis, A., Berns, A., Alentov, I., and Sergeeva, N., Serum levels of plasminogen activator urokinase receptor and cardiotrophin-like cytokine factor 1 in patients with nephrotic syndrome, Clin Nephrol, 2022, Vol 97(2) p. 103-110.
[20] da Silva, C. A., Araújo, L. S., Dos Reis Monteiro, M. L. G., de Morais Pereira, L. H., da Silva, M. V., Castellano, L. R. C., Corrêa, R. R. M., Dos Reis, M. A., and Machado, J. R., Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS, Dis Markers, 2019, Vol 2019 p. 1070495.
[21] Wei, C., Möller, C. C., Altintas, M. M., Li, J., Schwarz, K., Zacchigna, S., Xie, L., Henger, A., Schmid, H., Rastaldi, M. P., Cowan, P., Kretzler, M., Parrilla, R., Bendayan, M., Gupta, V., Nikolic, B., Kalluri, R., Carmeliet, P., Mundel, P., and Reiser, J., Modification of kidney barrier function by the urokinase receptor, Nat Med, 2008, Vol 14(1) p. 55-63. 10.1038/nm1696.
[22] Meijers, B., Maas, R. J. H., Sprangers, B., Claes, K., Poesen, R., Bammens, B., Naesens, M., Deegens, J. K. J., Dietrich, R., Storr, M., Wetzels, J. F. M., Evenepoel, P., and Kuypers, D., The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis, Kidney International, 2014, Vol 85(3) p. 636-640.
[23] Maas, R. J. H., Wetzels, J. F. M., and Deegens, J. K. J., Serum-soluble urokinase receptor concentration in primary FSGS, Kidney International, 2012, Vol 81(10) p. 1043-1044.
[24] Maas, R. J. H., Wetzels, J. F. M., and Deegens, J. K. J., Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease, Kidney International, 2014, Vol 85(3) p. 711.
[25] Maas, R. J. H., Deegens, J. K. J., and Wetzels, J. F. M., Serum suPAR in patients with FSGS: trash or treasure?, Pediatric Nephrology, 2013, Vol 28(7) p. 1041-1048. 10.1007/s00467-013-2452-5.
[26] Hayek, S. S., Tahhan, A. S., Ko, Y.-A., Alkhoder, A., Zheng, S., Bhimani, R., Hartsfield, J., Kim, J., Wilson, P., Shaw, L., Wei, C., Reiser, J., and Quyyumi, A. A., Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure, Journal of Cardiac Failure, 2023, Vol 29(2) p. 158-167.
[27] Mohammed, M. S. and Ahmed, H. S., Plasminogen activator urokinase receptor as a diagnostic and prognostic biomarker in type 2 diabetic patients with cardiovascular disease, J Cardiovasc Thorac Res, 2023, Vol 15(3) p. 154-160. 10.34172/jcvtr.2023.32895.
[28] Sharma, M., Zhou, J., Gauchat, J. F., Sharma, R., McCarthy, E. T., Srivastava, T., and Savin, V. J., Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier, Transl Res, 2015, Vol 166(4) p. 384-98.
[29] Savin, V. J., Sharma, M., Zhou, J., Gennochi, D., Fields, T., Sharma, R., McCarthy, E. T., Srivastava, T., Domen, J., Tormo, A., and Gauchat, J. F., Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family, J Immunol Res, 2015, Vol 2015 p. 714964.
[30] Savin, V. J., McCarthy, E. T., and Sharma, M., Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis, Kidney Res Clin Pract, 2012, Vol 31(4) p. 205-13.
[31] McCarthy, E. T., Sharma, M., and Savin, V. J., Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis, Clin J Am Soc Nephrol, 2010, Vol 5(11) p. 2115-21.
[32] Delville, M., Sigdel, T. K., Wei, C., Li, J., Hsieh, S. C., Fornoni, A., Burke, G. W., Bruneval, P., Naesens, M., Jackson, A., Alachkar, N., Canaud, G., Legendre, C., Anglicheau, D., Reiser, J., and Sarwal, M. M., A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation, Sci Transl Med, 2014, Vol 6(256) p. 256ra136.
[33] Komura, K., Fujimoto, M., Matsushita, T., Yanaba, K., Kodera, M., Kawasuji, A., Hasegawa, M., Takehara, K., and Sato, S., Increased serum soluble CD40 levels in patients with systemic sclerosis, J Rheumatol, 2007, Vol 34(2) p. 353-8.
[34] Liu, H., Qi, C. J., Zhuang, Y. M., Gan, J. H., Li, H. L., Yin, C. S., and Zhang, X. G., [Serum levels and clinical significance of soluble CD40 in liver disease], Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2006, Vol 22(6) p. 738-41.
[35] Chebotareva, N., Vinogradov, A., Birukova, Y., Alentov, I., Sergeeva, N., Chemodanova, D., Kononikhin, A. S., and Moiseev, S. V., A pilot study of anti-nephrin antibodies in podocytopaties among adults, Nephrology (Carlton), 2024, Vol 29(2) p. 86-92.
[36] Hengel Felicitas, E., Dehde, S., Lassé, M., Zahner, G., Seifert, L., Schnarre, A., Kretz, O., Demir, F., Pinnschmidt Hans, O., Grahammer, F., Lucas, R., Mehner Lea, M., Zimmermann, T., Billing Anja, M., Oh, J., Mitrotti, A., Pontrelli, P., Debiec, H., Dossier, C., Colucci, M., Emma, F., Smoyer William, E., Weins, A., Schaefer, F., Alachkar, N., Diemert, A., Hogan, J., Hoxha, E., Wiech, T., Rinschen Markus, M., Ronco, P., Vivarelli, M., Gesualdo, L., Tomas Nicola, M., and Huber Tobias, B., Autoantibodies Targeting Nephrin in Podocytopathies, New England Journal of Medicine, 2024, Vol 391(5) p. 422-433.
[37] Watts, A. J. B., Keller, K. H., Lerner, G., Rosales, I., Collins, A. B., Sekulic, M., Waikar, S. S., Chandraker, A., Riella, L. V., Alexander, M. P., Troost, J. P., Chen, J., Fermin, D., Yee, J. L., Sampson, M. G., Beck, L. H., Jr., Henderson, J. M., Greka, A., Rennke, H. G., and Weins, A., Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology, J Am Soc Nephrol, 2022, Vol 33(1) p. 238-252.
[38] Shirai, Y., Miura, K., Ishizuka, K., Ando, T., Kanda, S., Hashimoto, J., Hamasaki, Y., Hotta, K., Ito, N., Honda, K., Tanabe, K., Takano, T., and Hattori, M., A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence, Kidney Int, 2024, Vol 105(3) p. 608-617.
[39] Norio, R., Heredity in the congenital nephrotic syndrome. A genetic study of 57 finnish FAMILIES WITH A REVIEW OF REPORTED CASES, Ann Paediatr Fenn, 1966, Vol 12 p. Suppl 27:1-94.
[40] Kestilä, M., Lenkkeri, U., Männikkö, M., Lamerdin, J., McCready, P., Putaala, H., Ruotsalainen, V., Morita, T., Nissinen, M., Herva, R., Kashtan, C. E., Peltonen, L., Holmberg, C., Olsen, A., and Tryggvason, K., Positionally Cloned Gene for a Novel Glomerular Protein—Nephrin—Is Mutated in Congenital Nephrotic Syndrome, Molecular Cell, 1998, Vol 1(4) p. 575-582.
[41] Kestilä, M., Männikkö, M., Holmberg, C., Gyapay, G., Weissenbach, J., Savolainen, E. R., Peltonen, L., and Tryggvason, K., Congenital nephrotic syndrome of the Finnish type maps to the long arm of chromosome 19, Am J Hum Genet, 1994, Vol 54(5) p. 757-64.
[42] Ruotsalainen, V., Ljungberg, P., Wartiovaara, J., Lenkkeri, U., Kestilä, M., Jalanko, H., Holmberg, C., and Tryggvason, K., Nephrin is specifically located at the slit diaphragm of glomerular podocytes, Proc Natl Acad Sci U S A, 1999, Vol 96(14) p. 7962-7.
[43]Topham, P. S., Kawachi, H., Haydar, S. A., Chugh, S., Addona, T. A., Charron, K. B., Holzman, L. B., Shia, M., Shimizu, F., and Salant, D. J., Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin, J Clin Invest, 1999, Vol 104(11) p. 1559-66.
[44Holzman, L. B., St John, P. L., Kovari, I. A., Verma, R., Holthofer, H., and Abrahamson, D. R., Nephrin localizes to the slit pore of the glomerular epithelial cell, Kidney Int, 1999, Vol 56(4) p. 1481-91.
[45] Schoeb, D. S., Chernin, G., Heeringa, S. F., Matejas, V., Held, S., Vega-Warner, V., Bockenhauer, D., Vlangos, C. N., Moorani, K. N., Neuhaus, T. J., Kari, J. A., MacDonald, J., Saisawat, P., Ashraf, S., Ovunc, B., Zenker, M., and Hildebrandt, F., Nineteen novel NPHS1 mutations in a worldwide cohort of patients with congenital nephrotic syndrome (CNS), Nephrol Dial Transplant, 2010, Vol 25(9) p. 2970-6.
[46] Denhez, B. and Geraldes, P., "Regulation of Nephrin Phosphorylation in Diabetes and Chronic Kidney Injury", in Protein Reviews: Volume 18, M.Z. Atassi, Editor, Springer Singapore: Singapore. 2017. p. 149-161.
[47] Tian, Y., Chen, X.-m., Liang, X.-m., Wu, X.-b., and Yao, C.-m., SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial, Scientific Reports, 2022, Vol 12(1) p. 15695.
[48] Verma, R., Kovari, I., Soofi, A., Nihalani, D., Patrie, K., and Holzman, L. B., Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization, J Clin Invest, 2006, Vol 116(5) p. 1346-59.
[49] Jones, N., Blasutig, I. M., Eremina, V., Ruston, J. M., Bladt, F., Li, H., Huang, H., Larose, L., Li, S. S. C., Takano, T., Quaggin, S. E., and Pawson, T., Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes, Nature, 2006, Vol 440(7085) p. 818-823.
[50] Orikasa, M., Matsui, K., Oite, T., and Shimizu, F., , The Journal of Immunology, 1988, Vol 141(3) p. 807-814.
[51] Kikuchi, H., Kawachi, H., Ito, Y., Matsui, K., Nosaka, H., Saito, A., Orikasa, M., Arakawa, M., and Shimizu, F., Severe proteinuria, sustained for 6 months, induces tubular epithelial cell injury and cell infiltration in rats but not progressive interstitial fibrosis, Nephrology Dialysis Transplantation, 2000, Vol 15(6) p. 799-810.
[52] Bressendorff, I., Nelveg-Kristensen, K. E., Ghasemi, M., Watts, A. J. B., Elversang, J., Keller, K. H., Nielsen, F. C., Szpirt, W., and Weins, A., Antinephrin-Associated Primary Focal Segmental Glomerulosclerosis Successfully Treated With Plasmapheresis, Kidney International Reports, 2024, Vol 9(9) p. 2829-2831.
[53] Cui, Z. and Zhao, M.-h., Anti-nephrin autoantibodies: a paradigm shift in podocytopathies, Nature Reviews Nephrology, 2024, Vol 20(10) p. 639-640.
[54]Batal I, Watts AJB, Gibier JB, Hamroun A, Top I, Provot F, Keller K, Ye X, Fernandez HE, Leal R, Andeen NK, Crew RJ, Dube GK, Vasilescu ER, Ratner LE, Bowman N, Bomback AS, Sanna-Cherchi S, Kiryluk K, Weins A. Pre-transplant anti-nephrin antibodies are specific predictors of recurrent diffuse podocytopathy in the kidney allograft. Kidney Int. 2024 Oct;106(4):749-752. doi: 10.1016/j.kint.2024.07.022.
[55] Tanoue, A., Katayama, K., Ito, Y., Joh, K., Toda, M., Yasuma, T., D’Alessandro-Gabazza, C. N., Kawachi, H., Yan, K., Ito, M., Gabazza, E. C., Tryggvason, K., and Dohi, K., Podocyte-specific Crb2 knockout mice develop focal segmental glomerulosclerosis, Scientific Reports, 2021, Vol 11(1) p. 20556.
[56] Möller-Kerutt, A., Rodriguez-Gatica, J. E., Wacker, K., Bhatia, R., Siebrasse, J. P., Boon, N., Van Marck, V., Boor, P., Kubitscheck, U., Wijnholds, J., Pavenstädt, H., and Weide, T., Crumbs2 Is an Essential Slit Diaphragm Protein of the Renal Filtration Barrier, J Am Soc Nephrol, 2021, Vol 32(5) p. 1053-1070.
[57] Hada, I., Shimizu, A., Takematsu, H., Nishibori, Y., Kimura, T., Fukutomi, T., Kudo, A., Ito-Nitta, N., Kiuchi, Z., Patrakka, J., Mikami, N., Leclerc, S., Akimoto, Y., Hirayama, Y., Mori, S., Takano, T., and Yan, K., A Novel Mouse Model of Idiopathic Nephrotic Syndrome Induced by Immunization with the Podocyte Protein Crb2, J Am Soc Nephrol, 2022, Vol 33(11) p. 2008-2025.
[58] Carvajal Abreu, K., Loos, S., Fischer, L., Pape, L., Wiech, T., Kemper, M. J., Tönshoff, B., Oh, J., and Schild, R., Case report: Early onset de novo FSGS in a child after kidney transplantation—a successful treatment, 2023, Vol 11 p.
[59] Kim, Y.-J., Lee, S.-W., Kim, M.-S., Kim, Y.-J., Choi, J.-Y., Cho, J.-H., Kim, C.-D., Kim, Y.-L., Yun, W.-S., Huh, S., Lim, J.-H., and Park, S.-H., Anuria after kidney transplantation diagnosed as early recurrence of focal segmental glomerulosclerosis combined with acute calcineurin inhibitor nephrotoxicity: a case report and literature review, BMC Nephrology, 2024, Vol 25(1) p. 123.
[60]Alasfar S , Matar D , Montgomery RA ,et al. Rituximab and therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis postkidney transplantation[J]. Transplantation, 2018,102(3):e115-e120. DOI: 10.1097/TP.000000000000200